Adjuvant Therapy in Stage I Testicular Cancer: Surveillance for All
European Urology Focus · 2024
DOI: 10.1016/j.euf.2024.05.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Urology Focus, 2024. Verfasst von Stephan Brönimann und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, T…. Hauptthemen laut MEDLINE: Testicular Neoplasms, Neoplasm Staging. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Given the remarkably high cure rates for clinical stage (CS) I testicular cancer, the toxicities and risks of adjuvant treatments, the cost effectiveness of surveillance, and the lack of reliable biomarkers to predict relapse, surveillance should be recommended for all patients with CS I testicular cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Urology, The Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Brady Urological Institute, The Johns Hopkins University School of…
Zitieren
APA
Brönimann, S., & Singla, N. (2024). Adjuvant Therapy in Stage I Testicular Cancer: Surveillance for All. European Urology Focus. https://doi.org/10.1016/j.euf.2024.05.017
Vancouver
Brönimann S, Singla N. Adjuvant Therapy in Stage I Testicular Cancer: Surveillance for All. European Urology Focus. 2024. doi:10.1016/j.euf.2024.05.017
BibTeX
@article{Brnimann2024,
author = {Brönimann, Stephan and Singla, Nirmish},
title = {Adjuvant Therapy in Stage I Testicular Cancer: Surveillance for All},
journal = {European Urology Focus},
year = {2024},
doi = {10.1016/j.euf.2024.05.017}
}
EUVIMED